Skip to main content
Richard Riedel, MD, Oncology, Durham, NC

RichardFrancisRiedelMD

Oncology • Durham, NC

Associate Professor, Division of Medical Oncology, Department of Medicine, Duke University Medical Center

Join to view full profile

Dr. Riedel is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Riedel's full profile

Already have an account?

  • Office

    Campus Box 3841
    Dumc
    Durham, NC 27710
    Phone+1 919-684-8111

Education & Training

  • Duke University Hospital
    Duke University HospitalFellowship, Hematology and Medical Oncology, 2003 - 2007
  • Duke University Hospital
    Duke University HospitalResidency, Internal Medicine, 2000 - 2003
  • Sidney Kimmel Medical College at Thomas Jefferson University
    Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 2000

Certifications & Licensure

  • NC State Medical License
    NC State Medical License 2000 - 2025
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • The Experiences of Older Caregivers of Cancer Patients Following Hospital Discharge  
    Richard F Riedel, Ellen Mahoney, Thomas W LeBlanc, Cristina C Hendrix, Supportive care in cancer

Lectures

  • A randomized, double-blind, placebo-controlled, phase II study of regorafenib vs placebo in advanced/metastatic, treatment-refractory liposarcoma: results from the SAR... 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
  • Is There an Optimal Treatment Sequence for Systemic Therapy in Metastatic Disease? 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018

Press Mentions

  • Bad to the Bone: Emerging Approaches to Aggressive Bone Sarcomas
    Bad to the Bone: Emerging Approaches to Aggressive Bone SarcomasMay 1st, 2023
  • Epizyme’s Sarcoma Drug Sails Through FDA Panel with Unanimous Vote
    Epizyme’s Sarcoma Drug Sails Through FDA Panel with Unanimous VoteDecember 18th, 2019
  • Thumbs up from FDA Panel for Sarcoma Drug
    Thumbs up from FDA Panel for Sarcoma DrugDecember 18th, 2019
  • Join now to see all

Professional Memberships

Dr. Richard Riedel, Dr. Richard Riedel, MD, Dr. R Riedel, Dr. Richard Francis Riedel